The 12 references in paper V. Smirnov V., R. Abdrashitov H., E. Egorenkov A., G. Gildeeva N., G. Ramenskaya V., R. Permyakov A., Валерий Смирнов Валерьевич, Рустем Абдрашитов Хамзиевич, Евгений Егоренков Андреевич, Гэлия Гильдеева Нязыфовна, Галина Раменская Владиславовна, Роман Пермяков Александрович (2018) “Влияние изофермента CYP2D6 на метаболизм лекарственных препаратов и методы определения его активности // Influence of CYP2d6 on drug metabolism and methods for determining its activity” / spz:neicon:vedomostincesmp:y:2015:i:3:p:32-35

1
Kukes VG. Metabolism of drugs: clinical and pharmacological aspects. Moscow: Reafarm; 2004 (in Russian).
(check this in PDF content)
2
Caldwell J. Drug metabolism and pharmacogenetics: the British contribution to fields of international significance. Br J Pharmacol. 2006; 147: 89–99.
(check this in PDF content)
3
Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, Jukema JW. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J. 2012; 33(2): 165–75. R E F E R E N C E S Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation, 8 Petrovsky Boulevard, Moscow, 127051, Russian Federation. Smirnov VV. Leading researcher of Clinical Pharmacokinetics Department of Clinical Pharmacology Center. Candidate of Pharmaceutical Sciences. I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Street, Moscow, 119991, Russian Federation. Abdrashitov RH. Graduate student of the Department of Pharmaceutical and
(check this in PDF content)
4
Fux R, Morike K, Prohmer AM, Delabar U, Schwab M, Schaeffeler E, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005; 78: 378–87.
(check this in PDF content)
5
Nagele P, Liggett SB. Genetic variation, β-blockers, and perioperativemyocardial infarction. Anesthesiology 2011; 115: 1316–27.
(check this in PDF content)
6
Shams ME, Arneth B, Hiemke C. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006; 31: 493–502.
(check this in PDF content)
7
Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351: 2827–31.
(check this in PDF content)
8
Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007; 82: 87–96.
(check this in PDF content)
9
Lynch T, Price A. The effect of cytochrome P 450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007; 76(3): 391–6.
(check this in PDF content)
10
Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47: 75–85.
(check this in PDF content)
11
Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006; 57: 119−37.
(check this in PDF content)
12
Jiang XL, Shen HW, Yu AM. Pinoline may be used as a probe for CYP2D6 activity. Drug Metab Dispos. 2009; 37(3): 443–6. 4. Fux R, Morike K, Prohmer AM, Delabar U, Schwab M, Schaeffeler E, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 2005; 78: 378–87.
(check this in PDF content)